Stryker is a Michigan-based medical technology company with 52,000 employees, providing products in MedSurg, Neurotechnology, Orthopedics, and Spine to enhance healthcare outcomes. Their offerings include surgical equipment, neurointerventional devices, and Mako Robotic-Arm Assisted technology.
Based on our analysis, Stryker Corporation has received an overvalued rating of 1 out of 5 stars from Cashu. Several financial ratios indicate that the company may not be performing as well as its current valuation suggests.
The price-to-earnings (PE) ratio for Stryker stands at 50.95, significantly higher than the sector average of 14.18. A high PE ratio can indicate that a company's stock is overvalued relative to its earnings, which may deter potential investors looking for value.
Additionally, Stryker's price-to-book (PB) ratio is 6.65, compared to the sector average of 2.71. The PB ratio measures a company's market value relative to its book value. A higher PB ratio could imply that investors are paying a premium for the company's equity, raising concerns about sustainability in its valuation.
Furthermore, Stryker’s dividend yield is 0.85, which is lower than the sector average of 1.18. This lower yield may indicate that investors are not receiving competitive returns through dividends, which can be a red flag for income-seeking investors.
Lastly, while Stryker boasts a respectable return on equity (ROE) of 14.51, this figure is still modest compared to the sector average of -76.41. Despite performing better than its peers, this ratio indicates that the company is not generating as much profit from its equity as one might expect given its valuation.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.